STOCK TITAN
  1. Home
  2. News
  3. MXCT

MaxCyte Inc - MXCT STOCK NEWS

Welcome to our dedicated news page for MaxCyte (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on MaxCyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MaxCyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MaxCyte's position in the market.

News
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Rhea-AI Summary
MaxCyte, Inc. announced the release of financial results for the first quarter of 2024, scheduled after the U.S. market close on May 7th, 2024. The company, a cell-engineering focused organization, aims to advance cell therapeutics and bioprocessing applications. Investors can join the earnings conference call hosted by the management at 4:30 p.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences earnings
-
News
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Rhea-AI Summary
MaxCyte, Inc. partners with Be Biopharma to utilize Flow Electroporation® technology and ExPERT™ platform for Engineered B Cell Medicines programs. This strategic platform license agreement aims to advance the development of therapies for genetic diseases and cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
News
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Rhea-AI Summary
MaxCyte, Inc. announces fourth quarter and full year 2023 financial results with total revenue of $15.7 million in Q4, an increase of 26% over Q4 2022. Core business revenue declined by 32% in Q4. SPL Program-related revenue saw a significant increase of 359% in Q4. Full year 2023 total revenue was $41.3 million, a decline of 7% over 2022. The company ended the year with $211.2 million in cash, cash equivalents, and investments. Management reiterated 2024 revenue guidance with expectations of flat to 5% growth in core business revenue and SPL Program-related revenue of approximately $3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
earnings
News
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
Rhea-AI Summary
MaxCyte, Inc. provided revenue guidance for 2024, reaffirming 2023 preliminary results. Total revenue for 2023 expected to be $41.1-41.3 million, down from $44.3 million in 2022. Core revenue to be $29.6-29.8 million. SPL Program-related revenue to be $11.4 million. Cash, cash equivalents, and investments expected to be $210 million by Dec 31, 2023. 2024 guidance includes flat to 5% growth in core revenue and $3 million in SPL Program-related revenue. Management anticipates ending 2024 with $175 million in cash. MaxCyte signed three SPLs in 2024 to support cell and gene therapy clients. The company will present at the Cowen Healthcare Conference and release Q4 earnings on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.21%
Tags
none
-
News
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
Rhea-AI Summary
MaxCyte, Inc. announces the release of financial results for Q4 and full year 2023, along with upcoming investor conferences. The company focuses on cell-engineering technologies for cell therapeutics and bioprocessing applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences earnings
-
News
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
Rhea-AI Summary
MaxCyte, Inc. and Wugen, Inc. have signed a strategic platform license agreement, allowing Wugen to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for its programs targeting hematologic and solid tumor cancers. Wugen will gain non-exclusive clinical and commercial rights in exchange for annual license fees and program-related revenue. Wugen is developing off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer, with its lead program, WU-CART-007, currently in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. MaxCyte's ExPERT™ platform is expected to support efficient and seamless expansion to large-scale manufacturing for Wugen's therapies, ultimately impacting patients' lives. This marks MaxCyte's 26th clinical/commercial partnership, generating pre-commercial milestone revenue and sales-based payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
News
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
Rhea-AI Summary
MaxCyte, Inc. and Imugene announce a strategic platform license agreement for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support azer-cel, a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer, along with additional novel cell therapy programs. Imugene is rapidly moving towards a potential Phase 2 registrational trial for azer-cel in cancer, leveraging MaxCyte's scalable cell-engineering process and optimized clinical manufacturing workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
News
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
MaxCyte, a leading cell-engineering focused company providing enabling platform technologies, reported preliminary unaudited fourth quarter and full year 2023 results. Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022. Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022. MaxCyte's total cash, cash equivalents, and investments as of December 31, 2023, is expected to be approximately $210 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
earnings
-
News
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
Rhea-AI Summary
MaxCyte, Inc. (MXCT) partners with Lion TCR to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases, expanding MaxCyte's presence in Asia with anticipated expansion into the US and European markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.6%
Tags
partnership
News
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
Rhea-AI Summary
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT) appoints Maher Masoud as President and CEO, effective January 1, 2024, and discloses his stock options. The company focuses on cell-engineering technologies for cell therapeutics and bioprocessing applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
management
Stock MXCT logo
MaxCyte Inc

Nasdaq:MXCT

MXCT Rankings

#3180 Ranked by Market Cap
#4869 Ranked by Stock Gains
N/A Ranked by Dividends

MXCT Stock Data

431.88M
91.50M
1.3%
76.37%
3.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Gaithersburg

About MXCT

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.